|
|
|
International Clinical Trials
|
The exacting nature of regulatory submissions requires an organisation to maintain immaculate documentation that conforms to consistent and stringent configuration and organisation guidelines. Now, more than ever before, the use of technology is no longer a useful option, but a veritable necessity. Pharmaceutical and biologics organisations managing their product submissions and registrations rely heavily on content generated from clinical trials, making document management a critical component of these technological dependencies. The need for having industry-wide consistency of the management of these activities has resulted in the development of industry best practices such as the electronic document management (EDM) for electronic common technical document (eCTD) and trial master file (TMF) for clinical reference models maintaining clinical trial content in conformance with regulatory guidelines.
Connecting the Dots
The EDM reference model is a best practices reference that helps companies provide consistent naming, metadata, and documentation collections within a common structure industrywide. It is a document management initiative aimed at developing document organisation best practice based on eCTD to be shared by pharma and biologics organisations as a common starting point for building sustainable, shareable EDM repositories. The genesis of the EDM reference model was a direct result of technological improvements coinciding with and spurred by the ever-changing eCTD standards for metadata, XML navigation, study-tagging files (STFs), and regulatory information management (RIM). Because document management is a critical component of these technology dependencies, a model was needed to help organisations meet such demands in documents, taxonomies, and metadata. In an attempt to standardise these processes industrywide, members of the Drug Information Association (DIA) and Documents and Records Special Interest Area Community (SIAC) responded by forming a working group in 2008 to develop an EDM model “for the industry, from the industry, and by the industry” (1). The group’s aspiration was to develop a free, open, and sustainable model that would be flexible enough to allow every company to choose the software that would best meet their business needs.
“The goal of the EDM Reference Model is to provide a starting point to create harmonisation across the industry, making it easier for transactions between companies – because the architecture is the same,” EDM reference model core committee member Steve Scribner explains in the Guide to the DIA EDM Reference Model, Process Zone: Regulatory-Submissions (1).“ Even if data isn’t exactly the same, getting people to work together would be so much easier with a model.” The intended audience for the EDM reference model includes biopharma companies implementing an EDM system or a simple file share to store and prepare documents for regulatory submissions of drugs and biologic products intended for human use.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
PCI Pharma Services Announces Appointment of Angi Calkins as Chief Human Resources Officer
Philadelphia, PA – January 28, 2019. Leading biopharmaceutical services provider PCI Pharma Services (PCI) is pleased to announce the appointment of Angi Calkins as Senior Vice President and Chief Human Resources Officer. Angi joins PCI as the company experiences considerable growth and global expansion, currently with more than 3,500 associates, spanning eight locations comprised of 20 facilities across three continents. PCI features a broad portfolio of outsourced development and commercialization services focused in drug development and manufacturing, clinical trial supply, as well as commercial contract packaging.
More info >> |
|
 |
White Papers |
 |
|
Bringing more control to temperature-sensitive logistics
UPS Supply Chain Solutions
By 2016, world sales of cold-chain drugs and biologics such as vaccines and blood plasma products will near $240 billion1. The increase has led to a surge in discussion about how to protect these products throughout the transportation logistics cycle. Industry experts are recommending that the term “cold chain” be eliminated from rules, guidance and best-practice documents. “Cold chain” now includes
a broader spectrum of temperature ranges, such as controlled room temperature (CRT). This white paper focuses on the initial steps required to establish a temperature-sensitive supply chain.
More info >> |
|
 |
Industry Events |
 |
CPhI & P-MEC China
18-20 June 2019, SNIEC, Shanghai, China
CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >> |
|
|
